Drugmaker Harrow slumps after forecasting annual revenue below estimates

Shares of ophthalmic drugmaker Harrow HROW.O fall 14.9% to $45.69 premarket

Co said late on Monday that it expects 2026 revenue in the range of $350 million to $365 million, below analysts' average estimate of $386.25 million, according to LSEG compiled data

HROW reported Q4 revenue of $89.1 million, beating estimates of $88.45 million

As of last close, HROW stock up 9.4% YTD